These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18374459)

  • 1. Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation.
    Mizukami T; Imai J; Hamaguchi I; Kawamura M; Momose H; Naito S; Maeyama J; Masumi A; Kuramitsu M; Takizawa K; Nomura N; Watanabe S; Yamaguchi K
    Vaccine; 2008 Apr; 26(18):2270-83. PubMed ID: 18374459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.
    Lalor PA; Webby RJ; Morrow J; Rusalov D; Kaslow DC; Rolland A; Smith LR
    J Infect Dis; 2008 Jun; 197(12):1643-52. PubMed ID: 18513153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
    Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
    Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
    Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
    Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
    Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
    Ehrlich HJ; Müller M; Fritsch S; Zeitlinger M; Berezuk G; Löw-Baselli A; van der Velden MV; Pöllabauer EM; Maritsch F; Pavlova BG; Tambyah PA; Oh HM; Montomoli E; Kistner O; Noel Barrett P
    J Infect Dis; 2009 Oct; 200(7):1113-8. PubMed ID: 19712040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant fowlpox virus vector-based vaccine completely protects chickens from H5N1 avian influenza virus.
    Qiao C; Jiang Y; Tian G; Wang X; Li C; Xin X; Chen H; Yu K
    Antiviral Res; 2009 Mar; 81(3):234-8. PubMed ID: 19110002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.